INM vs SPRC
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The company exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe weakness across nearly all fundamental health dimensions. While the current ratio is high (5.94), this is offset by a catastrophic profit margin of -170.07% and declining year-over-year revenue growth of -26.20%. The stock is in a clear long-term death spiral, with a 5-year price change of -100% and a technical trend score of 0/100. Without a pivot to profitability or a significant capital infusion, the business model appears unsustainable.
SPRC exhibits severe financial distress, anchored by a weak Piotroski F-Score of 3/9 and a catastrophic ROE of -1281.49%. The company has experienced a massive valuation collapse, falling from a 52-week high of $94.50 to $4.42, representing a 91.7% decline over the last year. With an operating margin of -569.52% and a total lack of analyst coverage, the business model appears unsustainable. The recent 1-week price spike of 40.3% is likely a speculative 'dead cat bounce' rather than a fundamental recovery.
Compare Another Pair
Related Comparisons
INM vs SPRC: Head-to-Head Comparison
This page compares InMed Pharmaceuticals Inc. (INM) and SciSparc Ltd. (SPRC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.